Vanguard Group’s Cellectis CLLS Stock Holding History

Vanguard Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-85,864	Closed	-$197K	–	4532
2022 Q3	$197K	Buy	+85,864	New	+$260K	﹤0.01%	4419

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group's CLLS Position: Q4 2022 in Review

Vanguard Group sold out of Cellectis (CLLS) in Q4 2022, closing a stake of 85,864 shares — an estimated $197K sold.

Vanguard Group first reported a position in CLLS in Q3 2022 and held it in 1 quarter. The position peaked at $197K in Q3 2022. 40 funds tracked by Wall St. Rank hold CLLS as of Q4 2022.

Vanguard Group reported no remaining Cellectis position as of Q4 2022 after selling out during the quarter.
Vanguard Group sold 85,864 Cellectis shares in Q4 2022, an estimated $197K.
Vanguard Group first reported a position in Cellectis in Q3 2022 and held it in 1 quarter.
Vanguard Group's Cellectis position peaked at $197K in Q3 2022.
40 funds tracked by Wall St. Rank held Cellectis as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.